June 2026 Quarterly Update and Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
Additionally, Dr. Rosalind Wilson was appointed as Chief Medical Officer, effective mid-July, to lead the clinical development strategy. The report also details the company's engagement at major industry events to foster partnerships and advance its clinical programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- March 2026 Quarterly Update and Appendix 4C
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
Later from Prescient Therapeutics
- Appendix 4E and 2026 Annual Report
- Prescient Therapeutics Opens SPP to Raise $7m Today
- PTX-100 CTCL Phase 2a study reaches review milestone
- PTX Successfully Completes $6m Raise Via SPP and Placement
- September 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics